The Influence of Family History on Stage and Survival of Gastric Cancer According to the <i>TGFB1</i> C-509T Polymorphism in Korea

Abstract

Background/Aims: The survival rate of gastric cancer (GC) is known to be higher in patients with a family history (FH) of GC. There is an association between a polymorphism in the transforming growth factor-β1 (TGFB1) gene and the risk of GC in patients with first-degree relatives with GC. This study was performed to investigate whether a FH affects GC outcomes according to the TGFB1 C-509T polymorphism. Methods: TGFB1 was genotyped by the polymerase chain reaction-restriction fragment length polymorphism method in 1,143 GC patients, including 216 patients (18.9%) with firstdegree relatives with GC. Results: The proportion of stage I-II GCs was significantly higher in patients with a FH than in those without a FH of GC (83.8 vs 74.9%, p=0.005). The association between a FH of GC and stage I-II GC was not significant in subgroups divided based on the TGFB1 C-509T polymorphism and sex. A FH did not affect the overall survival rate of GC in patient with all stages and each stage. The overall survival rates were not significantly different between patients with the CC and CT/TT genotypes of the TGFB1-509 polymorphism. Conclusions: Patient with a FH of GC had lower cancer stage (I-II) at diagnosis than those without a FH of GC, but there was no significant difference in overall survival between the patients with and without a FH of GC. A FH did not influence the tumor stage or overall survival in patients stratified by the presence of the TGFB1 C-509T polymorphism. (Gut Liver 2020;14:79-88)

Effect of Helicobacter pylori eradication after subtotal gastrectomy on the survival rate of patients with gastric cancer: follow-up for up to 15 years

“…The HP infection status was determined by histologic examination with the Giemsa staining method, the rapid urease test (CLOtest, Delta West Ltd., Bentley, WA Australia) and/ or culture from the antrum and body, respectively, when GC was diagnosed by biopsy [21]. The diagnosis of GC was confirmed again histologically with removed surgical specimen.…”

Promising aberrant DNA methylation marker to predict gastric cancer development in individuals with family history and long-term effects of H. pylori eradication on DNA methylation

“…Single nucleotide polymorphisms related to cytokines such as transforming growth factor-β1 and interleukin-1 have been investigated to establish genetic predisposition in GC patients with FH [14,15]. Additionally, GC patients with FH present a lower cancer stage (I-II) at diagnosis than those without FH, but overall survival was not different between patients with and without FH [16].…”

Evaluation of Important Molecular Pathways and Candidate Diagnostic Biomarkers of Noninvasive to Invasive Stages in Gastric Cancer by In Silico Analysis

“…Most studies are about the mutations, variants, and polymorphisms of TGFB1 with gastric cancer. For example, the C-509T [ 38 ] and 509C/T [ 39 ] mutations were significantly associated with gastric cancer invasion. Therefore, in this study, by performing bioinformatics analysis, we showed that TGFB1 could also be considered as a diagnostic biomarker for gastric cancer.…”